Fundz
Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly. See plans and pricing.See plans →

Moonwalk Biosciences secures $70 million in Series B financing to advance its adipose-targeted RNAi therapies for obesity and related diseases.

PRIVATESep 08, 2026•about 3 hours ago

Amount Raised

$70 Million

Round Type

Series B

San FranciscoBiotechnology

Description

Moonwalk Biosciences has announced the closure of its $70 million Series B financing round. This funding will support the advancement of their innovative RNAi therapies targeting adipose tissue. The investment aims to tackle obesity and cardiometabolic diseases. The financing round marked a significant milestone in their continued development efforts.

Company Information

Company

Moonwalk Biosciences

Location

2 TOWER PLACE, 17TH FLOOR

San Francisco, California, United States

About

Moonwalk Biosciences is an early-stage therapeutics company co-founded by Dr. Feng Zhang and leading experts in cell state epigenetics including Alex Aravanis, the former CTO of Illumina. The company has developed a differentiated approach to mapping the epigenome of cellular states at the whole genome, single cell resolution level, as well as proprietary strategies for precise epigenetic engineering. The combination enables both a novel discovery platform and a path to developing therapeutics that include both epigenetic engineering and other traditional modalities.

Don't miss Moonwalk Biosciences's next move

Get an email the moment Moonwalk Biosciences raises, hires an exec, or expands, usually minutes after it happens.

One email per event. Unsubscribe anytime.

Related People

Suggested for you
1 contact
Predictive Intelligence
Strategic

ML-powered predictions for Moonwalk Biosciences's next move

See what Strategic adds

Funding Insights

Based on industry data
Timeline to next round
Series B companies typically work for 15-20 months before raising new capital
Growth expectations
Series B companies are expected to scale rapidly and expand market reach
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Moonwalk Biosciences raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.